Trigemina Announces Expansion Of Phase 2 Study Of TI-001 For Chronic Migraine
Published: Feb 06, 2014
MORAGA, Calif., Feb. 6, 2014 (GLOBE NEWSWIRE) -- Trigemina, Inc., a biopharmaceutical company focused on the discovery and development of non-narcotic, nasally delivered, analgesic drug products, today announced it has expanded its Phase II clinical study for TI-001, intranasal oxytocin, beyond Chile to include sites in Brisbane and Adelaide, Australia.
Help employers find you! Check out all the jobs and post your resume.